An observational study in Appendicitis, Intestinal Metaplasia and Metabonomics, sponsored by HongyiQu. Recruiting at 1 site in China. Open to participants aged 1 Year to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by HongyiQu · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Appendicitis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Appendicitis · China.
Among the 17 studies in Appendicitis with a site in China, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 11th registered.
421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.
Browse Appendicitis studies →6 of the 17 studies in Appendicitis with a site in China are open now. Recruiting first, the newest first:
Nanchong Central Hospital · Sites in China
Ages 18+
Changhai Hospital · Sites in China
Ages 18+
Southern Medical University, China · Sites in China
Healthy volunteers
Huaping Xie · Sites in China
Ages 18–75 · Healthy volunteers
Kecheng Zhang · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 200 across 151 observational studies indexed under Appendicitis.
Median enrollment 200 across the 13 interventional studies, 140 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with HongyiQu as lead sponsor.
HongyiQu has 1 study filed under Appendicitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Appendicitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07230379Changhai HospitalDirect Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis | 2026-12 |
| NCT07478029Huaping XieClinical Study of PEG Bowel Preparation in Appendectomy Patients | 2027-02-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Appendicitis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the key bacterial flora and metabolites associated with appendicitis in children. The main questions it aims to answer are:
Participants will detect feces using 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology and differences of the fecal metabolites between healthy children and appendicitis children were analyzed using untargeted metabolomics based on Liquid chromatography-tandem mass spectrometry(LC-M S/MS) platform.Through the analysis of intestinal bacterial flora and metabolomics association and the differential analysis of intestinal bacterial flora in different parts of the case group, the key bacterial flora and metabolites were excavated.
Participants will detect feces using 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology and differences of the fecal metabolites between healthy children and appendicitis children were analyzed using untargeted metabolomics based on Liquid chromatography-tandem mass spectrometry(LC-M S/MS) platform.
Differences in the intestinal flora of different parts of the case group: the intestinal flora of the case group in feces and rectum were detected by 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology, and the intestinal flora of different parts were analyzed and compared.
Through the analysis of intestinal bacterial flora and metabolomics association and the differential analysis of intestinal bacterial flora in different parts of the case group, the key bacterial flora and metabolites were excavated.
Children aged 1-14 in Department of Pediatric Surgery in Shandong Qianfoshan Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children with appendectomy for appendicitis
Children with no digestive disease or medical history
The 16S rRNA gene sequence
Samples were qualified for Polymerase Chain Reaction(PCR) amplification of the V3 and V4 variable regions of the 16 rRNA gene. The Polymerase Chain Reaction(PCR) products were then quantified by confirming the presence of PCR amplicons by gel electrophoresis on a 2% agarose gel and staining with ethidium bromide, and equimolar amounts (100 ng) of PCR amplicons were pooled prior to pyrosequencing. High-throughput sequencing of the qualified 16S amplicon libraries.
Time frame: up to 24 weeks
Fecal untargeted metabolomics testing
To analyze the fecal metabolite differences and the correlation of appendicitis and metabolites using untargeted metabolomics based on the LC-M S/MS platform. To screen key metabolites in pediatric appendicitis.
Time frame: up to 24 weeks
Started Apr 2023 (actual). Primary completion is estimated for Jan 2025, 21 months after the start.
Of 54 non-industry observational studies under Appendicitis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 21 months is close to that.
Counting every sponsor, half of 56 studies reached it within 23 months; a quarter within 7 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.